GLP1R and diabetes mellitus: To date, the main randomized control trial (RCT) addressing erectile outcomes with GLP-1 RA therapy is an exploratory analysis of the REWIND (Researching Cardiovascular Events With a Weekly INcretin in Diabetes) trial.